• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aridis Pharmaceuticals Inc.

    7/27/21 1:20:59 PM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDS alert in real time by email
    SC 13G 1 tm2123282d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.     )*

     

    Aridis Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    040334104

    (CUSIP Number)

     

    July 20, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 040334104

     
      1. Name of Reporting Person
    AstraZeneca PLC
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x  (Joint filers)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United Kingdom
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    884,956 shares1
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    884,956 shares2
     
    8. Shared Dispositive Power
    0 shares
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    884,956 shares3
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    7.3%4
     
      12. Type of Reporting Person (See Instructions)
    CO
               

     

     

    1 Represents shares directly held by MedImmune Limited, a wholly-owned indirect subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over the shares.

    2 See footnote 1.

    3 See footnote 1.

    4 The percentage ownership was calculated based on a denominator which is the sum of (i) 11,232,921 shares of the issuer’s common stock outstanding as of April 30, 2021, as reported in the issuer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the “Form 10-Q”) filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2021 and (ii) the 884,956 shares of the issuer’s common stock held by the Reporting Persons.

     

    Page 2 of 6

     

     

    CUSIP No. 040334104
     
      1. Name of Reporting Person
    MedImmune Limited
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x  (Joint filers)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United Kingdom
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    884,956 shares5
     
    6. Shared Voting Power
    0 shares
     
    7. Sole Dispositive Power
    884,956 shares6
     
    8. Shared Dispositive Power
    0 shares
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    884,956 shares7
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    7.3%8
     
      12. Type of Reporting Person (See Instructions)
    CO
               

     

     

    5 See footnote 1.

    6 See footnote 1.

    7 See footnote 1.

    8 See footnote 4.

     

    Page 3 of 6

     

     

    Item 1.
     
      (a)

    Name of Issuer
    Aridis Pharmaceuticals, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices
    983 University Avenue

    Building B
    Los Gatos, California 95032

     

     
    Item 2.
     
      (a)

    Name of Person Filing
    See response to 2(c)

     

      (b)

    Address of Principal Business Office or, if none, Residence
    See response to 2(c)

     

      (c)

    Citizenship
    This statement is filed on behalf of:

     

    AstraZeneca PLC

    1 Francis Crick Avenue

    Cambridge Biomedical Campus

    Cambridge CB2 0AA

    United Kingdom

    Citizenship: United Kingdom

     

    MedImmune Limited

    Milstein Building

    Granta Park

    Cambridge CB21 6GH

    United Kingdom

    Citizenship: United Kingdom

     

      (d)

    Title of Class of Securities
    Common Stock, par value $0.0001 per share

     

      (e)

    CUSIP Number
    040334104

     

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
           
      (k) ¨

    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

    § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 4 of 6

     

     

    Item 4. Ownership
       
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
      (a)

    Amount beneficially owned:

    884,956 shares

     

      (b)

    Percent of class:

    7.3%. The percentage ownership was calculated based on a denominator which is the sum of (i) 11,232,921 shares of the issuer’s common stock outstanding as of April 30, 2021, as reported in the Form 10-Q filed with the SEC on May 11, 2021 and (ii) the 884,956 shares of the issuer’s common stock held by the Reporting Persons.

     

      (c)

    Number of shares as to which the person has:

     

        (i)

    Sole power to vote or to direct the vote:

     

    AstraZeneca PLC: 884,956 shares

     

    MedImmune Limited: 884,956 shares

        (ii)

    Shared power to vote or to direct the vote:

     

    AstraZeneca PLC: 0 shares

     

    MedImmune Limited: 0 shares

        (iii)

    Sole power to dispose or to direct the disposition of:

     

    AstraZeneca PLC: 884,956 shares

     

    MedImmune Limited: 884,956 shares

        (iv)

    Shared power to dispose or to direct the disposition of:

     

    AstraZeneca PLC: 0 shares

     

    MedImmune Limited: 0 shares

     

    MedImmune Limited, a wholly-owned indirect subsidiary of AstraZeneca PLC, is the direct record holder of all 884,956 shares reported herein. Each of MedImmune Limited and AstraZeneca PLC may be deemed to have sole voting and dispositive power with respect to such shares.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
    Not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
    Not applicable.
     
    Item 8. Identification and Classification of Members of the Group
       
    Not applicable.
     
    Item 9. Notice of Dissolution of Group
       
    Not applicable.
     
    Item 10. Certifications
       
    Not applicable.

     

    Material Filed as Exhibits

     

    Exhibit 99           Joint Filing Agreement between AstraZeneca PLC and MedImmune Limited

     

    Page 5 of 6

     

     

    Signatures

     

    After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    July 27, 2021

     

      AstraZeneca PLC

     

     

    /s/ Adrian Kemp

      Signature
       
     
    Adrian Kemp, Company Secretary
      Name/Title

     

      MedImmune Limited

     


    /s/ Matthew Bowden

      Signature
       
     
    Matthew Bowden, Director
      Name/Title

     

    Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

     

    Page 6 of 6

    Get the next $ARDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDS

    DatePrice TargetRatingAnalyst
    7/20/2021$11.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Aridis Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $11.00 previously

      7/20/21 6:08:15 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Securities resumed coverage on Aridis Pharmaceuticals with a new price target

      Northland Securities resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      2/24/21 4:13:46 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Aridis Pharmaceuticals with a new price target

      Roth Capital resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      1/24/21 2:54:23 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Financials

    Live finance-specific insights

    See more

    $ARDS
    SEC Filings

    See more

    $ARDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ARDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ARDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The

      9/15/23 9:00:00 AM ET
      $ARDS
      $AREC
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Coal Mining
      Energy
    • Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals (NASDAQ:ARDS): https://www.aridispharmainfo.com/interview_accessRail Vision (NASDAQ:RVSN): https://www.rvsninfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' expe

      6/30/23 9:00:00 AM ET
      $ARDS
      $RVSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Railroads
      Industrials
    • Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      6/27/24 4:15:22 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      1/16/24 6:05:19 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Aridis Pharmaceuticals Inc.

      DEFA14A - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      12/18/23 9:43:08 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Provides Corporate Update

      LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. Company update: The Company continues to diligently explore multiple paths to monetize its assets amidst a protracted challenging capital market and limited internal resources. During the second half of this year it has been in discussions with other pharmaceutical companies and investment firms on possible partnerships and investments in the clinical product candidates AR-301, AR-320, AR-501, and the APEX platform technology. The Company has substantially reduced its operational

      12/20/24 8:00:00 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Provides Corporate Update

      LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. The Company has been in sustained discussions with other pharmaceutical companies and investment firms on possible partnerships and investments on its clinical product candidates AR- 301, AR-320, AR-501, and the APEX platform technology. The principal goal for the discussions has been to build shareholder value by out-licensing or attracting capital investments to complete the final stages of product development. A summary of the status of the major programs is further highlight

      6/24/24 5:58:04 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

      Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023. Third Quarter Highlights Received a grant award from the National Institute of Allergy and Infectious Diseases (NIAID) division of the National Institutes of Health (NIH), in collaboration with researchers at

      11/3/23 4:15:00 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hamilton John F

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 8:36:10 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Windham-Bannister Susan Richards

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 8:36:12 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Jafri Hasan

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:46:52 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Patzer Eric bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 419% to 884,600 units (SEC Form 4)

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:32:40 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Truong Vu bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 108% to 1,378,639 units (SEC Form 4)

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:29:41 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      11/14/24 4:46:40 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      2/14/24 2:21:52 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      2/13/24 8:02:49 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care